Tecovirimat for Clade I MPXV Infection in the Democratic Republic of Congo

Tecovirimat did not reduce the number of days to lesion resolution in patients with mpox caused by clade I MPXV. No safety concerns were identified. (Funded by the National Institute of Allergy and Infectious Diseases and others; PALM007 ClinicalTrials.gov number, NCT05559099.).

Institutions

Publication Details

Journal
New England Journal of Medicine
Published
2025-04-16
DOI
https://doi.org/10.1056/nejmoa2412439
Citations
69
Primary Topic
Poxvirus research and outbreaks
Type
article
Field-Weighted Citation Impact
71.50

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Tecovirimat for Clade I MPXV Infection in the Democratic Republic of Congo

69 citations
New England Journal of Medicine
Poxvirus research and outbreaks
71.50
article

Tecovirimat for Clade I MPXV Infection in the Democratic Republic of Congo

article en
69 citations

Abstract

Tecovirimat did not reduce the number of days to lesion resolution in patients with mpox caused by clade I MPXV. No safety concerns were identified. (Funded by the National Institute of Allergy and Infectious Diseases and others; PALM007 ClinicalTrials.gov number, NCT05559099.).

New England Journal of MedicineVol. 392(15)
National Institute of Biomedical Research (CD)
National Institute of Allergy and Infectious Diseases
Openalex Percentile: Top 0%
Poxvirus research and outbreaks
71.50
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.